U.S. Preventive Services Task Force (USPSTF). Recommendations: cardiovascular disorders (heart and vascular diseases); development and behavior; metabolic, nutritional, and endocrine conditions; and miscellaneous https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results?topic_status=P&category%5B%5D=16&category%5B%5D=17&category%5B%5D=21&category%5B%5D=26&searchterm=
Liss DT, Uchida T, Wilkes CL, Radakrishnan A, Linder JA. General health checks in adult primary care: a review. JAMA. 2021;325(22):2294-2306
Dyakova M, Shantikumar S, Colquitt JL. Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2016(1):CD010411
Jørgensen T, Jacobsen RK, Toft U, Aadahl M, Glümer C, Pisinger C. Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial. BMJ. 2014;348:g3617
Engberg M, Christensen B, Karlsmose B, Lous J, Lauritzen T. General health screenings to improve cardiovascular risk profiles: a randomized controlled trial in general practice with 5-year follow-up. J Fam Pract. 2002;51(6):546-552
Arena R, Arnett DK, Terry PE. The role of worksite health screening: a policy statement from the American Heart Association. Circulation. 2014;130(8):719-734
Feigin VL, Brainin M, Norrving B. What is the best mix of population-wide and high-risk targeted strategies of primary stroke and cardiovascular disease prevention?. J Am Heart Assoc. 2020;9(3):e014494
Food and Drug Administration. Final determination regarding partially hydrogenated oils. Fed Regist. 2015;80(116):34650
Goff DC, Lloyd-Jones DM, Bennett G. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;63(25 Pt B):2935-2959
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847
Rodondi N, Locatelli I, Aujesky D. Framingham risk score and alternatives for prediction of coronary heart disease in older adults. PLoS One. 2012;7(3):e34287
Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243-2251
Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611-619
Australian Chronic Disease Prevention Alliance. Australian absolute cardiovascular disease risk calculator https://www.cvdcheck.org.au/calculator
Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099
European Association of Preventive Cardiology. HeartScore: the interactive tool for predicting and managing the risk of heart attack and stroke https://www.heartscore.org/
Grundy SM, Stone NJ, Bailey AL. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143
Muntner P, Colantonio LD, Cushman M. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311(14):1406-1415
Rana JS, Tabada GH, Solomon MD. Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J Am Coll Cardiol. 2016;67(18):2118-2130
DeFilippis AP, Young R, McEvoy JW. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J. 2017;38(8):598-608
Rodriguez F, Chung S, Blum MR, Coulet A, Basu S, Palaniappan LP. Atherosclerotic cardiovascular disease risk prediction in disaggregated Asian and Hispanic subgroups using electronic health records. J Am Heart Assoc. 2019;8(14):e011874
Karmali KN, Persell SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017(3):CD006887
Phillips LS, Branch WT, Cook CB. Clinical inertia. Ann Intern Med. 2001;135(9):825-834
Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the Coronary Health Assessment study. BMJ. 1995;310(6985):975-978
Meland E, Laerum E, Stensvold I. Assessment of coronary heart disease risk, I. A postal inquiry among primary care physicians. Fam Pract. 1994;11(2):117-121
Meland E, Laerum E, Lehmann EH. Assessment of coronary heart disease risk, II. A clinical multicentre study of general practitioners’ risk assessment. Fam Pract. 1994;11(2):122-126
Sheridan SL, Viera AJ, Krantz MJ. The effect of giving global coronary risk information to adults: a systematic review. Arch Intern Med. 2010;170(3):230-239
Fiore MC, Jaen CR, Baker TB. Treating tobacco use and dependence: 2008 update. Clinical practice guideline https://www.ncbi.nlm.nih.gov/books/NBK63952
Jensen MD, Ryan DH, Apovian CM. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(Suppl 2):S102-S138
Virani SS, Alonso A, Aparicio HJ. Heart disease and stroke statistics–2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254-e743
Krist AH, Davidson KW. Screening for hypertension in adults: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2021;325(16):1650-1656
Whelton PK, Carey RM, Aronow WS. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324
Jonas DE, Crotty K, Yun JDY. Screening for prediabetes and type 2 diabetes: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2021;326(8):744-760
Zhang X, Gregg EW, Williamson DF. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010;33(7):1665-1673
Lindström J, IIanne-Parikka P, Peltonen M. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finish Diabetes Prevention study. Lancet. 2006;368(9548):1673-1679
Davidson KW, Barry MJ, Mangione CM. Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement. JAMA. 2021;326(8):736-743
Buse JB, Ginsberg HN, Bakris GL. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162-172
Arnett DK, Blumenthal RS, Albert MA. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177-e232
Muhlestein JB, Knowlton K, Le VT. Effect on patient adherence to primary prevention recommendations for statin therapy based on the national guidelines-supported pooled cohort risk equation or a coronary artery calcium score: preliminary findings from the Vanguard Study for the CorCal randomized clinical outcomes trial. J Am Coll Cardiol. 2020;75(11 Suppl 1):5
Lloyd-Jones DM, Hong Y, Labarthe D. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic impact goal through 2020 and beyond. Circulation. 2010;121(4):586-613
Lloyd-Jones DM, Allen NB, Anderson CAM. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a Presidential Advisory from the American Heart Association. Circulation. 2022;146(5):e18-e43
Yoon PW, Bastian B, Anderson RN, Collins JL, Jaffe HW. Potentially preventable deaths from the five leading causes of death— United States, 2008-2010. MMWR Morb Mortal Wkly Rep. 2014;63(17):369-374
Krist AH, Davidson KW, Mangione CM. Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors. US Preventive Services Task Force recommendation statement. JAMA. 2020;324(20):2069-2075
O’Connor EA, Evans CV, Rushkin MC, Redmond N, Lin JS. Behavioral counseling to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2020;324(20):2076-2094
Benjamin EJ, Blaha MJ, Chiuve SE. Heart disease and stroke statistics–2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146-e603
Younus A, Aneni EC, Spatz ES. A systematic review of the prevalence and outcomes of ideal cardiovascular health in US and non-US populations. Mayo Clin Proc. 2016;91(5):649-670
Aneni EC, Crippa A, Osondu CU. Estimates of mortality benefit from ideal cardiovascular health metrics: a dose response meta-analysis. J Am Heart Assoc. 2017;6(12):e006904
Valero-Elizondo J, Salami JA, Ogunmoroti O. Favorable cardiovascular risk profile is associated with lower healthcare costs and resource utilization: the 2012 Medical Expenditure Panel Survey. Circ Cardiovasc Qual Outcomes. 2016;9(2):143-153
Osondu CU, Aneni EC, Valero-Elizondo J. Favorable cardiovascular health is associated with lower health care expenditures and resource utilization in a large US employee population: the Baptist Health South Florida Employee Study. Mayo Clin Proc. 2017;92(4):512-524
Patnode CD, Henderson JT, Coppola EL, Melnikow J, Durbin S, Thomas RG. Interventions for tobacco cessation in adults, including pregnant persons: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2021;325(3):280-298
Yu E, Malik VS, Hu FB. Cardiovascular disease prevention by diet modification: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(8):914-926
Wu H, Flint AJ, Qi Q. Association between dietary whole grain intake and risk of mortality: two large prospective studies in US men and women. JAMA Intern Med. 2015;175(3):373-384
Drouin-Chartier JP, Brassard D, Tessier-Grenier M. Systematic review of the association between dairy product consumption and risk of cardiovascular-related clinical outcomes. Adv Nutr. 2016;7(6):1026-1040
Krittanawong C, Narasimhan B, Wang Z. Association between egg consumption and risk of cardiovascular outcomes: a systematic review and meta-analysis. Am J Med. 2021;134(1):76-83.e2
Mazidi M, Katsiki N, Mikhailidis DP, Pencina MJ, Banach M. Egg consumption and risk of total and cause-specific mortality: an individual-based cohort study and pooling prospective studies on behalf of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. J Am Coll Nutr. 2019;38(6):552-563
Pan A, Sun Q, Bernstein AM. Red meat consumption and mortality: results from 2 prospective cohort studies. Arch Intern Med. 2012;172(7):555-563
Micha R, Michas G, Mozaffarian D. Unprocessed red and processed meats and risk of coronary artery disease and type 2 diabetes—an updated review of the evidence. Curr Atheroscler Rep. 2012;14(6):515-524
Gonçalves C, Abreu S. Sodium and potassium intake and cardiovascular disease in older people: a systematic review. Nutrients. 2020;12(11):3447
Adler AJ, Taylor F, Martin N, Gottlieb S, Taylor RS, Ebrahim S. Reduced dietary salt for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014(12):CD009217
Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011;342:d671
Ren Y, Liu Y, Sun XZ. Chocolate consumption and risk of cardiovascular diseases: a meta-analysis of prospective studies. Heart. 2019;105(1):49-55
Schwingshackl L, Missbach B, Hoffmann G. An umbrella review of garlic intake and risk of cardiovascular disease. Phytomedicine. 2016;23(11):1127-1133
Johnston BC, Kanters S, Bandayrel K. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA. 2014;312(9):923-933
Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293(1):43-53
de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. 2019;381(26):2541-2551
Yang F, Liu C, Liu X. Effect of epidemic intermittent fasting on cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials. Front Nutr. 2021;8:669325
Horne BD, Muhlestein JB, May HT. Relation of routine, periodic fasting to risk of diabetes mellitus, and coronary artery disease in patients undergoing coronary angiography. Am J Cardiol. 2012;109(11):1558-1562
Horne BD, May HT, Anderson JL. Usefulness of routine periodic fasting to lower risk of coronary artery disease in patients undergoing coronary angiography. Am J Cardiol. 2008;102(7):814-819
Horne BD, Muhlestein JB, Anderson JL. Health effects of intermittent fasting: hormesis or harm? A systematic review. Am J Clin Nutr. 2015;102(2):464-470
D’Souza MS, Dong TA, Ragazzo G. From fad to fact: evaluating the impact of emerging diets on the prevention of cardiovascular disease. Am J Med. 2020;133(10):1126-1134
Moreno B, Bellido D, Sajoux I. Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity. Endocrine. 2014;47(3):793-805
Castellana M, Conte E, Cignarelli A. Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: a systematic review and meta-analysis. Rev Endocr Metab Disord. 2020;21(1):5-16
Siervo M, Lara J, Chowdhury S, Ashor A, Oggioni C, Mathers JC. Effects of the Dietary Approach to Stop Hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta-analysis. Br J Nutr. 2015;113(1):1-15
Chiavaroli L, Viguiliouk E, Nishi SK. DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses. Nutrients. 2019;11(2):338
Saneei P, Salehi-Abargouei A, Esmaillzadeh A, Azadbakht L. Influence of Dietary Approaches to Stop Hypertension (DASH) diet on blood pressure: a systematic review and meta-analysis on randomized controlled trials. Nutr Metab Cardiovasc Dis. 2014;24(12):1253-1261
Salehi-Abargouei A, Maghsoudi Z, Shirani F, Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases—incidence: a systematic review and meta-analysis on observational prospective studies. Nutrition. 2013;29(4):611-618
Rosato V, Temple NJ, La Vecchia C, Castellan G, Tavani A, Guercio V. Mediterranean diet and cardiovascular disease: a systematic review and meta-analysis of observational studies. Eur J Nutr. 2019;58(1):173-191
Becerra-Tomás N, Blanco Mejía S, Viguiliouk E. Mediterranean diet, cardiovascular disease and mortality in diabetes: a systematic review and meta-analysis of prospective cohort studies and randomized clinical trials. Crit Rev Food Sci Nutr. 2020;60(7):1207-1227
Grosso G, Marventano S, Yang J. A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: are individual components equal?. Crit Rev Food Sci Nutr. 2017;57(15):3218-3232
Troiano RP, Berrigan D, Dodd KW, Mâsse LC, Tilert T, McDowell M. Physical activity in the United States measured by accelerometer. Med Sci Sports Exerc. 2008;40(1):181-188
Kraus WE, Powell KE, Haskell WL. Physical activity, all-cause and cardiovascular mortality, and cardiovascular disease. Med Sci Sports Exerc. 2019;51(6):1270-1281
Franco OH, de Laet C, Peeters A, Jonker J, Mackenbach J, Nusselder W. Effects of physical activity on life expectancy with cardiovascular disease. Arch Intern Med. 2005;165(20):2355-2360
Katzmarzyk PT, Lee IM. Sedentary behaviour and life expectancy in the USA: a cause-deleted life table analysis. BMJ Open. 2012;2(4):e000828
Jayedi A, Gohari A, Shab-Bidar S. Daily step count and all-cause mortality: a dose-response meta-analysis of prospective cohort studies. Sports Med. 2022;52(1):89-99
Williams MA, Haskell WL, Ades PA. Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2007;116(5):572-584
Liu Y, Lee DC, Li Y. Associations of resistance exercise with cardiovascular disease morbidity and mortality. Med Sci Sports Exerc. 2019;51(3):499-508
Hardcastle SJ, Taylor AH, Bailey MP, Harley RA, Hagger MS. Effectiveness of a motivational interviewing intervention on weight loss, physical activity and cardiovascular disease risk factors: a randomised controlled trial with a 12-month post-intervention follow-up. Int J Behav Nutr Phys Act. 2013;10:40
Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164(12):836-845
Baigent C, Blackwell L, Collins R. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-1860
Gaziano JM, Brotons C, Coppolecchia R. Use of Aspirin to Reduce Risk of Initial Vascular Events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-1046
Bowman L, Mafham M, Wallendszus K. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529-1539
Visseren FLJ, Mach G, Smulders YM. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337
Davidson KW, Barry MJ, Mangione CM. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA. 2022;327(16):1577-1584
Skinner JS, Cooper A. Secondary prevention of ischaemic cardiac events. BMJ Clin Evid. 2011;2011:206
Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168(1):6-15
Bibbins-Domingo K, Grossman DC, Curry SJ. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;316(19):1997-2007
Taylor F, Huffman MD, Macedo AF. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013(1):CD004816
Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407-415
Gencer B, Marston NA, Im K. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637-1643
Sabatine MS, Giugliano RP, Wiviott SD. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500-1509
Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019;381(16):1557-1567
Ray KK, Bays HE, Catapano AL. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022-1032
Goldberg AC, Leiter LA, Stroes ESG. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322(18):1780-1788
Raal FJ, Rosenson RS, Reeskamp LF. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711-720
Bhatt DL, Steg PG, Miller M. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22
Nicholls SJ, Lincoff AM, Garcia M. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk. The STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268-2280
Ray KK, Wright RS, Kallend D. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519
Khan SA, Naz A, Qamar Masood M, Shah R. Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Am J Cardiol. 2020;134:69-73
Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419
Muñoz D, Uzoije P, Reynolds C. Polypill for cardiovascular disease prevention in an underserved population. N Engl J Med. 2019;381(12):1114-1123
Chow CK, Atkins ER, Hillis GS. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398(10305):1043-1052
Yusuf S, Joseph P, Dans A. Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med. 2021;384(3):216-228
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(Suppl 1):S111-S124
American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(Suppl 1):S125-S150
Kim J, Choi J, Kwon SY. Association of multivitamin and mineral supplementation and risk of cardiovascular disease: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2018;11(7):e004224
Chen F, Du M, Blumberg JB. Association among dietary supplement use, nutrient intake, and mortality among U.S. adults: a cohort study. Ann Intern Med. 2019;170(9):604-613
Khan SU, Khan MU, Riaz H. Effects of nutritional supplements and dietary interventions on cardiovascular outcomes. An umbrella review and evidence map. Ann Intern Med. 2019;171(3):190-198
Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953
Wing RR, Bolin P, Brancati FL. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-154
Yates T, Haffner SM, Schulte PJ. Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. Lancet. 2014;383(9922):1059-1066
American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(Suppl 1):S73-S84
James PA, Oparil S, Carter BL. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality. Lancet. 2002;360:1903-1913
Ettehad D, Emdin CA, Kiran A. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-967
Ogunmoroti O, Allen NB, Cushman M. Association between Life’s Simple 7 and non-cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2016;5(10):e003954
Qaseem A, Wilt TJ, Rich R. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017;166(6):430-437
Williamson JD, Supiano MA, Applegate WB. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults ≥75 years: a randomized clinical trial. JAMA. 2016;315(24):2673-2682
Lonn EM, Yusuf S. Should patients with cardiovascular risk factors receive intensive treatment of hypertension to <120/80 mm Hg target? An antagonist view from the HOPE-3 trial (Heart Outcomes Evaluation-3). Circulation. 2016;134(18):1311-1313
Oparil S, Lewis CE. Should patients with cardiovascular risk factors receive intensive treatment of hypertension to <120/80 mm Hg target? A protagonist view from the SPRINT Trial (Systolic Blood Pressure Intervention Trial). Circulation. 2016;134(18):1308-1310
Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625-1636
Lindson-Hawley N, Thompson TP, Begh R. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev. 2015(3):CD006936
Rothemich SF, Woolf SH, Johnson RE. Effect on cessation counseling of documenting smoking status as a routine vital sign: an ACORN study. Ann Fam Med. 2008;6(1):60-68
Agency for Healthcare Research and Quality. Five major steps to intervention (The “5 A’s”) https://www.ahrq.gov/prevention/guidelines/tobacco/5steps.html
Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014(1):CD000031
Drugs for smoking cessation. Med Lett Drugs Ther. 2019;61(1576):105-110
Leone FT, Zhang Y, Evers-Casey S. Initiating pharmacologic treatment in tobacco-dependent adults. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;202(2):e5-e31
Food and Drug Administration. FDA Drug Safety Communication: Chantix (varenicline) drug label now contains updated efficacy and safety information https://www.fda.gov/Drugs/DrugSafety/ucm264436.htm
Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2013(8):CD002850
Fryar CD, Carroll MD, Afful J. Prevalence of overweight, obesity and severe obesity among adults aged 20 and over: United States, 1960-1962 through 2017-2018 https://www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/obesity-adult.htm
Ahern AL, Wheeler GM, Aveyard P. Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial. Lancet. 2017;389(10085):2214-2225
Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74-86
Khera R, Murad MH, Chandar AK. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424-2434
Davies M, Færch L, Jeppesen OK. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984
Diet, drugs, devices, and surgery for weight management. Med Lett Drugs Ther. 2018;60(1548):91-98
Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014(8):CD003641
Vest AR, Heneghan HM, Agarwal S, Schauer PR, Young JB. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart. 2012;98(24):1763-1777
Sjöholm K, Anveden A, Peltonen M. Evaluation of current eligibility criteria for bariatric surgery: diabetes prevention and risk factor changes in the Swedish obese subjects (SOS) study. Diabetes Care. 2013;36(5):1335-1340
Reges O, Greenland P, Dicker D. Association of bariatric surgery using laparoscopic banding, Roux-en-y gastric bypass, or laparoscopic sleeve gastrectomy vs usual care obesity management with all-cause mortality. JAMA. 2018;319(3):279-290
Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta. 2018;484:150-163
Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 2011;97(11):870-875
Kloner RA, Carson C, Dobs A, Kopecky S, Mohler ER. Testosterone and cardiovascular disease. J Am Coll Cardiol. 2016;67(5):545-557
Khan SU, Javed Z, Lone AN. Social vulnerability and premature cardiovascular mortality among US counties, 2014 to 2018. Circulation. 2021;144(16):1272-1279
He J, Zhu Z, Bundy JD, Dorans KS, Chen J, Hamm LL. Trends in cardiovascular risk factors in US adults by race and ethnicity and socioeconomic status, 1999-2018. JAMA. 2021;326(13):1286-1298
Billioux A, Verlander K, Anthony S, Alley D. Standardized screening for health-related social needs in clinical settings: the Accountable Health Communities Screening Tool. NAM Perspectives. 2017